XKRX
235980
Market cap63mUSD
Jul 10, Last price
2,810.00KRW
1D
1.08%
1Q
-45.65%
IPO
-94.88%
Name
MedPacto Inc
Chart & Performance
P/E
—
P/S
24.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-72.98%
Rev. gr., 5y
%
Revenues
3.90b
Net income
-12.80b
L-36.43%
CFO
-13.39b
L-19.14%
Dividend
Mar 15, 20220.285 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MedPacto, Inc. is a South Korean biopharmaceutical company specializing in the research and development of novel therapeutic solutions for oncology and autoimmune conditions. The firm's pipeline includes several key drug candidates: ME-1601mAb, an investigational treatment designed to target BSP1 for various cancers; MS-1601A, which addresses both cancerous and autoimmune diseases by targeting TRG1; and vactosertib, a therapeutic candidate aimed at solid tumors. MedPacto is headquartered in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||